Clinical utility of RAS mutations in thyroid cancer: A blurred picture now emerging clearer

Research output: Contribution to journalArticle

Abstract

RAS mutations play an important role in thyroid tumorigenesis. Considerable effort has been made in the last decade to apply RAS mutations as molecular markers to the clinical management of thyroid nodules and thyroid cancer. Yet, for the low diagnostic sensitivities and specificities of RAS mutations, when used alone, and for their uncertain role in the clinical outcomes of thyroid cancer, it has been unclear how to appropriately use them to assist the management of thyroid nodules and thyroid cancer. Studies from recent years, now added from the Alexander group, have shed light on this issue, making a blurred clinical picture now emerge clearer-RAS mutations, when combined with other genetic markers, have high diagnostic negative predictive values for thyroid cancer; cytologically benign thyroid nodules, including those positive for RAS mutations, have long-term clinical stability when non-surgically managed; and differentiated thyroid cancers harboring RAS mutations alone have an excellent prognosis. This progress in understanding RAS mutations in thyroid cancer is showing a major impact on molecular-based practice in the management of thyroid cancer. Please see related research articles: http://dx.doi.org/10.1186/s12916-016-0554-1 and http://dx.doi.org/10.1186/s12916-015-0419-z

Original languageEnglish (US)
JournalBMC Medicine
DOIs
StateAccepted/In press - Jan 27 2016

Fingerprint

Thyroid Neoplasms
Mutation
Thyroid Nodule
Practice Management
Genetic Markers
Thyroid Gland
Carcinogenesis
Biomarkers
Sensitivity and Specificity
Research

Keywords

  • Diagnosis
  • Molecular marker
  • Prognosis
  • RAS mutation
  • Thyroid cancer
  • Thyroid nodule

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{fd5e7b599e7a468a9d327c59befc75bb,
title = "Clinical utility of RAS mutations in thyroid cancer: A blurred picture now emerging clearer",
abstract = "RAS mutations play an important role in thyroid tumorigenesis. Considerable effort has been made in the last decade to apply RAS mutations as molecular markers to the clinical management of thyroid nodules and thyroid cancer. Yet, for the low diagnostic sensitivities and specificities of RAS mutations, when used alone, and for their uncertain role in the clinical outcomes of thyroid cancer, it has been unclear how to appropriately use them to assist the management of thyroid nodules and thyroid cancer. Studies from recent years, now added from the Alexander group, have shed light on this issue, making a blurred clinical picture now emerge clearer-RAS mutations, when combined with other genetic markers, have high diagnostic negative predictive values for thyroid cancer; cytologically benign thyroid nodules, including those positive for RAS mutations, have long-term clinical stability when non-surgically managed; and differentiated thyroid cancers harboring RAS mutations alone have an excellent prognosis. This progress in understanding RAS mutations in thyroid cancer is showing a major impact on molecular-based practice in the management of thyroid cancer. Please see related research articles: http://dx.doi.org/10.1186/s12916-016-0554-1 and http://dx.doi.org/10.1186/s12916-015-0419-z",
keywords = "Diagnosis, Molecular marker, Prognosis, RAS mutation, Thyroid cancer, Thyroid nodule",
author = "Xing, {Michael Mingzhao}",
year = "2016",
month = "1",
day = "27",
doi = "10.1186/s12916-016-0559-9",
language = "English (US)",
journal = "BMC Medicine",
issn = "1741-7015",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Clinical utility of RAS mutations in thyroid cancer

T2 - A blurred picture now emerging clearer

AU - Xing, Michael Mingzhao

PY - 2016/1/27

Y1 - 2016/1/27

N2 - RAS mutations play an important role in thyroid tumorigenesis. Considerable effort has been made in the last decade to apply RAS mutations as molecular markers to the clinical management of thyroid nodules and thyroid cancer. Yet, for the low diagnostic sensitivities and specificities of RAS mutations, when used alone, and for their uncertain role in the clinical outcomes of thyroid cancer, it has been unclear how to appropriately use them to assist the management of thyroid nodules and thyroid cancer. Studies from recent years, now added from the Alexander group, have shed light on this issue, making a blurred clinical picture now emerge clearer-RAS mutations, when combined with other genetic markers, have high diagnostic negative predictive values for thyroid cancer; cytologically benign thyroid nodules, including those positive for RAS mutations, have long-term clinical stability when non-surgically managed; and differentiated thyroid cancers harboring RAS mutations alone have an excellent prognosis. This progress in understanding RAS mutations in thyroid cancer is showing a major impact on molecular-based practice in the management of thyroid cancer. Please see related research articles: http://dx.doi.org/10.1186/s12916-016-0554-1 and http://dx.doi.org/10.1186/s12916-015-0419-z

AB - RAS mutations play an important role in thyroid tumorigenesis. Considerable effort has been made in the last decade to apply RAS mutations as molecular markers to the clinical management of thyroid nodules and thyroid cancer. Yet, for the low diagnostic sensitivities and specificities of RAS mutations, when used alone, and for their uncertain role in the clinical outcomes of thyroid cancer, it has been unclear how to appropriately use them to assist the management of thyroid nodules and thyroid cancer. Studies from recent years, now added from the Alexander group, have shed light on this issue, making a blurred clinical picture now emerge clearer-RAS mutations, when combined with other genetic markers, have high diagnostic negative predictive values for thyroid cancer; cytologically benign thyroid nodules, including those positive for RAS mutations, have long-term clinical stability when non-surgically managed; and differentiated thyroid cancers harboring RAS mutations alone have an excellent prognosis. This progress in understanding RAS mutations in thyroid cancer is showing a major impact on molecular-based practice in the management of thyroid cancer. Please see related research articles: http://dx.doi.org/10.1186/s12916-016-0554-1 and http://dx.doi.org/10.1186/s12916-015-0419-z

KW - Diagnosis

KW - Molecular marker

KW - Prognosis

KW - RAS mutation

KW - Thyroid cancer

KW - Thyroid nodule

UR - http://www.scopus.com/inward/record.url?scp=84955296314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955296314&partnerID=8YFLogxK

U2 - 10.1186/s12916-016-0559-9

DO - 10.1186/s12916-016-0559-9

M3 - Article

C2 - 26817707

AN - SCOPUS:84955296314

JO - BMC Medicine

JF - BMC Medicine

SN - 1741-7015

ER -